eprotirome
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00776321)
Timeline
Indications
Mechanism of action
THRB agonist
Development discontinued in 2012 due to cartilage damage seen in animal study (http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=6395352)
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cc(Oc2c(Br)cc(NC(=O)CC(=O)O)cc2Br)ccc1O- Mol. weight
- 487.14 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2035874 ↗
Also known as
- 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid
- eprotirome
- eprotirome
- eprotirome
- eprotirome
- eprotirome
- kb2115
- kb2115
- kb2115
- kb 2115
- kb-2115
- kb-2115
- kb-2115
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01410383 | Phase 3 | Oct 1, 2011 | Karo Bio AB, University of Amsterdam |
| NCT00677248 | Phase 2 | Apr 1, 2008 | Karo Bio AB |
| NCT00593047 | Phase 2 | Nov 1, 2007 | Karo Bio AB |
| NCT00776321 | Phase 2 | Sep 1, 2006 | Karo Bio AB |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Karo Bio AB | For profit | 4 | 4 | 2 | 2006 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1